Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Commercial Officer | October 15, 2022 | October 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date October 15, 2022 · Filed October 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 9,993 |
Reported balance
After 2022-10-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-10-15 · Exercise / conversion · Acquired 5,000 · Balance 9,993 F1: Includes 312 shares purchased through the Company's employee stock purchase plan. |
| Common stockSEC Table I · non-derivative | Direct | 8,508 |
Reported balance
After 2022-10-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-10-17 · Tax withholding · Disposed 1,485 · Balance 8,508 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-15 · Exercise / conversion · Disposed 5,000 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 312 shares purchased through the Company's employee stock purchase plan.
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3: The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2022 Filed Oct 18, 2022 20:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,485 | $27.48 | $40,807.80 |
DisclosureSEC source: 0001439222-22-000091 · wf-form4_166612418262958.xml · nonDerivative · entry 2 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,508 Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000091 · wf-form4_166612418262958.xml · derivative · entry 3 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022. F3 · derivative.expiration_date: The restricted stock units were granted on October 15, 2020. The shares underlying the restricted stock units will vest in full on October 15, 2022. Read SEC document |
| October 15, 2022 Filed Oct 18, 2022 20:17 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000091 · wf-form4_166612418262958.xml · nonDerivative · entry 1 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 312 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 41,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001439222-22-000027 · wf-form4_164634176855340.xml · derivative · entry 2 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common stock · 41,000 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:09 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000027 · wf-form4_164634176855340.xml · derivative · entry 1 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common stock · 11,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000020 · wf-form4_164565067739124.xml · derivative · entry 5 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 658 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F4 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 742 | $29.08 | $21,577.36 |
DisclosureSEC source: 0001439222-22-000020 · wf-form4_164565067739124.xml · nonDerivative · entry 3 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,441 Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000020 · wf-form4_164565067739124.xml · nonDerivative · entry 2 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 1,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000020 · wf-form4_164565067739124.xml · derivative · entry 4 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,883 Underlying: Common stock · 1,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:11 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,884 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000020 · wf-form4_164565067739124.xml · nonDerivative · entry 1 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:00 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000010 · wf-form4_164504883633702.xml · derivative · entry 3 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,738 Underlying: Common stock · 1,738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:00 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 590 | $30.50 | $17,995.00 |
DisclosureSEC source: 0001439222-22-000010 · wf-form4_164504883633702.xml · nonDerivative · entry 2 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,641 Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:00 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000010 · wf-form4_164504883633702.xml · nonDerivative · entry 1 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000003 · wf-form4_164487275264401.xml · derivative · entry 3 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,136 Underlying: Common stock · 2,068 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 725 | $31.43 | $22,783.13 |
DisclosureSEC source: 0001439222-22-000003 · wf-form4_164487275264401.xml · nonDerivative · entry 2 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,493 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000003 · wf-form4_164487275264401.xml · nonDerivative · entry 1 Poddar Richa · CIK 0001897274 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.